<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772824</url>
  </required_header>
  <id_info>
    <org_study_id>GLU_07</org_study_id>
    <nct_id>NCT00772824</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients</brief_title>
  <official_title>Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients- A Prospective, Randomised, Single Blind, Three Arm, Phase Four Prevention Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banaras Hindu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banaras Hindu University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glutamine, a non essential branched chain amino acid, is most important non toxic nitrogen
      carrier in body. It participates in variety of physiological functions. It is a major fuel
      source of enterocytes and is a substrate for gluconeogenesis in kidney, lymphocytes, and
      monocytes. It is also a nutrient in muscle protein metabolism in response to infection,
      inflammation and muscle trauma. The significance of glutamine to metabolic homeostasis
      becomes evident during periods of stress, when it becomes a conditionally essential amino
      acid. Role of glutamine as protective agent in hepato-biliary dysfunction, in maintaining
      mucosal integrity of the Gastrointestinal tract following its administration in patient with
      major bowel surgery as a supplement and part of TPN in critically ill patients and in
      patients of septicemia, is well established. However the role of glutamine supplementation in
      reducing or preventing chemotherapeutic agents induced toxicity in cancer patients is
      controversial.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in toxicity</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum level of creatinine kinase and LDH</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>10 patients (30 cycles) of chemotherapy will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous glutamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Glutamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glutamine</intervention_name>
    <description>2g/kg body weight twice daily in divided doses for 5 days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IV Glutamine</intervention_name>
    <description>50 ml of 20% glutamine IV before chemotherapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients &gt; 18 years of age

          -  Histologically or cytologically proven breast cancer

          -  Receiving CEF chemotherapy cycles presently or in the past

          -  The patients who will give informed consent to participate in the study

          -  Patients must have sufficient organ and marrow function

          -  Stage 1 neuropathy, subclinical neuropathy, surgery induced neuropathy

        Exclusion Criteria:

          -  Pregnancy

          -  Clinical/biochemical severe liver failure

          -  Clinical/biochemical severe renal dysfunction

          -  Refusal to participate in the study

          -  Patients who have received prior chemotherapy with paclitaxel.

          -  Patients who have neuropathy due to any known systemic or metabolic causes like
             diabetes, leprosy, nutritional deficiency induced (vit. B12) etc
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R K Goel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manoj Pandey, MS</last_name>
    <phone>915422309511</phone>
    <email>manojpandey@vsnl.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deepika Joshi, MD, DM</last_name>
    <phone>915422307576</phone>
    <email>oncosurgery@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sir Sunder Lal Hospital</name>
      <address>
        <city>Varanasi</city>
        <state>UP</state>
        <zip>221005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manoj Pandey, MS</last_name>
      <phone>915422309511</phone>
      <email>manojpandey@vsnl.com</email>
    </contact>
    <investigator>
      <last_name>R K Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Bergström J, Fürst P, Norée LO, Vinnars E. Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol. 1974 Jun;36(6):693-7.</citation>
    <PMID>4829908</PMID>
  </reference>
  <reference>
    <citation>Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? Nutr Rev. 1990 Aug;48(8):297-309. Review.</citation>
    <PMID>2080048</PMID>
  </reference>
  <reference>
    <citation>Daniele B, Perrone F, Gallo C, Pignata S, De Martino S, De Vivo R, Barletta E, Tambaro R, Abbiati R, D'Agostino L. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut. 2001 Jan;48(1):28-33.</citation>
    <PMID>11115819</PMID>
  </reference>
  <reference>
    <citation>Rubio IT, Cao Y, Hutchins LF, Westbrook KC, Klimberg VS. Effect of glutamine on methotrexate efficacy and toxicity. Ann Surg. 1998 May;227(5):772-8; discussion 778-80.</citation>
    <PMID>9605669</PMID>
  </reference>
  <reference>
    <citation>Satoh J, Tsujikawa T, Fujiyama Y, Bamba T. Nutritional benefits of enteral alanyl-glutamine supplementation on rat small intestinal damage induced by cyclophosphamide. J Gastroenterol Hepatol. 2003 Jun;18(6):719-25.</citation>
    <PMID>12753156</PMID>
  </reference>
  <reference>
    <citation>van der Hulst RR, van Kreel BK, von Meyenfeldt MF, Brummer RJ, Arends JW, Deutz NE, Soeters PB. Glutamine and the preservation of gut integrity. Lancet. 1993 May 29;341(8857):1363-5.</citation>
    <PMID>8098788</PMID>
  </reference>
  <reference>
    <citation>Govindarajan R, Heaton KM, Broadwater R, Zeitlin A, Lang NP, Hauer-Jensen M. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet. 2000 Aug 12;356(9229):566-7.</citation>
    <PMID>10950238</PMID>
  </reference>
  <reference>
    <citation>Berthrong M. Pathologic changes secondary to radiation. World J Surg. 1986 Apr;10(2):155-70.</citation>
    <PMID>3705602</PMID>
  </reference>
  <reference>
    <citation>Huang EY, Leung SW, Wang CJ, Chen HC, Sun LM, Fang FM, Yeh SA, Hsu HC, Hsiung CY. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):535-9.</citation>
    <PMID>10701731</PMID>
  </reference>
  <reference>
    <citation>Cao Y, Kennedy R, Klimberg VS. Glutamine protects against doxorubicin-induced cardiotoxicity. J Surg Res. 1999 Jul;85(1):178-82.</citation>
    <PMID>10383856</PMID>
  </reference>
  <reference>
    <citation>Boyle FM, Wheeler HR, Shenfield GM. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol. 1999 Jan;41(2):107-16.</citation>
    <PMID>10222430</PMID>
  </reference>
  <reference>
    <citation>Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res. 2001 May;7(5):1192-7.</citation>
    <PMID>11350883</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2008</study_first_submitted>
  <study_first_submitted_qc>October 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <last_update_submitted>August 10, 2009</last_update_submitted>
  <last_update_submitted_qc>August 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Manoj Pandey, Head, Surgical Oncology</name_title>
    <organization>Institute of Medical Sciences</organization>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Epirubicin</keyword>
  <keyword>Glutamine</keyword>
  <keyword>FEC chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

